Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acadia, Avenue, Biontech, Celcuity, GBT, Hemogenyx, Hillstream, Jixing, Lexeo, Mirati, Moderna, Pfizer, Revive, Sirnaomics, Swanbio.
More than 100 million people worldwide are thought to have post-acute COVID-19 syndrome, roughly 40% of everyone on the planet who’s had COVID. Now, thousands of them are beginning to cycle through clinical and preclinical studies designed to get a better look at this little understood aspect of the pandemic.
The number of biopharma deals with nonprofits or government entities has dropped over last year, partly due to fewer COVID-19-related alliances, but the activity in 2022 is still strong in comparison to pre-pandemic years.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascletis, Axcella, Avion, Bavarian Nordic, Cidara.
It's neither a retrovirus nor an opportunistic infection. But of course, SARS-CoV-2 has a prominent place at the table at the 2022 Conference on Retroviruses and Opportunistic Infections (CROI) –
starting with the fact that COVID-19 has again forced the conference to go virtual.
China’s NMPA has given conditional approval to Pfizer Inc.’s COVID-19 oral pill Paxlovid (nirmatrelvir/ritonavir). The drug was approved for the treatment of adults with mild to moderate COVID-19 and a high risk of progression to severe disease. This includes the elderly, and people with chronic kidney issues, diabetes, cardiovascular, and chronic lung disease.
RSS
